Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo

Amino Acids

Volumn 42, Issue 2-3, 2012, Pages 549-558

  Olsen, Rachelle R ^a   Chung, Ivy ^b   Zetter, Bruce R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Antizyme inhibitor; Cell proliferation; Prostate cancer; Tumor growth

Indexed keywords

ANTIZYME INHIBITOR 1; CELL PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AZIN1 PROTEIN, HUMAN; CARRIER PROTEIN; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STABLE EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ARTICLE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

MUS MUSCULUS; RATTUS;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CARRIER PROTEINS; CELL LINE, TUMOR; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84861684351     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1032-x     Document Type: Article

References (48)

1. Agostinelli E, Marques MP, Calheiros R, Gil FP, Tempera G, Viceconte N, Battaglia V, Grancara S, Toninello A (2010) Polyamines: fundamental characters in chemistry and biology. Amino Acids 38(2):393-403. doi:10.1007/s00726-009- 0396-7
2. Auvinen M, Paasinen A, Andersson LC, Holtta E (1992) Ornithine decarboxylase activity is critical for cell transformation. Nature 360(6402):355-358. doi:10.1038/360355a0 (Pubitemid 23000675)
3. Bachrach U (2004) Polyamines and cancer: minireview article. Amino Acids 26(4):307-309. doi:10.1007/s00726-004-0076-6 (Pubitemid 39093131)
4. Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, Havighurst TC, Carbone PP (2010) A randomized, double-blind, placebocontrolled phase 3 skin cancer prevention study of {alpha}- difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res 3(1):35-47. doi:10.1158/1940-6207. capr-09-0096
5. Basuroy UK, Gerner EW (2006) Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem 139(1):27-33. doi: 10.1093/jb/mvj022 (Pubitemid 43258843)
6. Choi KS, Suh YH, Kim WH, Lee TH, Jung MH (2005) Stable siRNAmediated silencing of antizyme inhibitor: regulation of ornithine decarboxylase activity. Biochem Biophys Res Commun 328(1):206-212. doi:10.1016/j.bbrc.2004.11.172
7. Coffino P (2001a) Antizyme, a mediator of ubiquitin-independent proteasomal degradation. Biochimie 83(3-4):319-323 (Pubitemid 32293652)
8. Coffino P (2001b) Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2(3):188-194. doi:10.1038/35056508 (Pubitemid 33675743)
9. Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4(10):781-792. doi:10.1038/nrc1454 (Pubitemid 39331150)
10. Gruendler C, Lin Y, Farley J, Wang T (2001) Proteasomal degradation of Smad1 induced by bone morphogenetic proteins. J Biol Chem 276(49):46533-46543. doi:10.1074/jbc.M105500200
11. Jung MH, Kim SC, Jeon GA, Kim SH, Kim Y, Choi KS, Park SI, Joe MK, Kimm K (2000) Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics 69(3):281-286. doi:10.1006/geno.2000.6338
12. Kahana C, Asher G, Shaul Y (2005) Mechanisms of protein degradation: an odyssey with ODC. Cell Cycle 4(11):1461-1464
13. Keren-Paz A, Bercovich Z, Kahana C (2007) Antizyme inhibitor: a defective ornithine decarboxylase or a physiological regulator of polyamine biosynthesis and cellular proliferation. Biochem Soc Trans 35(Pt 2):311-313. doi:10.1042/bst0350311 (Pubitemid 46596497)
14. Keren-Paz A, Bercovich Z, Porat Z, Erez O, Brener O, Kahana C (2006) Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions. Oncogene 25(37):5163-5172. doi:10.1038/ sj.onc.1209521 (Pubitemid 44285985)
15. Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR (2006) Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism. J Cell Sci 119(Pt 12):2583-2591. doi:10.1242/ jcs.02966 (Pubitemid 44070439)
16. Lan L, Trempus C, Gilmour SK (2000) Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice. Cancer Res 60(20):5696-5703
17. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, YungWK, PradosMD, Bruner JM, Ictech S,Gleason MJ,KimHW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha- difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981-990 (Pubitemid 36323701)
18. Li X, Coffino P (1992) Regulated degradation of ornithine decarboxylase requires interaction with the polyamine-inducible protein antizyme. Mol Cell Biol 12(8):3556-3562
19. Lim SK, Gopalan G (2007) Antizyme1 mediates AURKAIP1- dependent degradation of Aurora-A. Oncogene 26(46):6593-6603. doi:10.1038/sj.onc.1210482 (Pubitemid 47573681)
20. Mangold U (2006) Antizyme inhibitor: mysterious modulator of cell proliferation. Cell Mol Life Sci 63(18):2095-2101. doi:10.1007/ s00018-005-5583-4 (Pubitemid 44465684)
21. Mangold U, Hayakawa H, Coughlin M, Munger K, Zetter BR (2008) Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification. Oncogene 27(5):604-613. doi: 10.1038/sj.onc.1210685 (Pubitemid 351158895)
22. Matsufuji S, Matsufuji T, Miyazaki Y, Murakami Y, Atkins JF, Gesteland RF, Hayashi S (1995) Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 80(1):51-60
23. Megosh L, Gilmour SK, Rosson D, Soler AP, Blessing M, Sawicki JA, O'Brien TG (1995) Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res 55(19):4205-4209
24. Meyskens FL Jr, Gerner EW (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5(5):945-951 (Pubitemid 29233206)
25. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM,Hawk E,Kelloff G, LawsonMJ,Kidao J, McCracken J,Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.Cancer PrevRes 1(1):32-38. doi:10.1158/1940-6207.capr-08-0042
26. Mi Z, Kramer DL, Miller JT, Bergeron RJ, Bernacki R, Porter CW (1998) Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate 34(1):51-60 (Pubitemid 28023826)
27. Murakami Y, Ichiba T, Matsufuji S, Hayashi S (1996) Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. J Biol Chem 271(7):3340-3342 (Pubitemid 26065634)
28. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka K, Ichihara A (1992) Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360(6404):597-599. doi:10.1038/360597a0 (Pubitemid 23000711)
29. Murakami Y, Suzuki J, Samejima K, Kikuchi K, Hascilowicz T, Murai N, Matsufuji S, Oka T (2009) The change of antizyme inhibitor expression and its possible role during mammalian cell cycle. Exp Cell Res 315(13):2301-2311. doi:10.1016/j.yexcr. 2009.04.024
30. Murakami Y, Suzuki J, Samejima K, Oka T (2010) Developmental alterations in expression and subcellular localization of antizyme and antizyme inhibitor and their functional importance in the murine mammary gland. Amino Acids 38(2):591-601. doi: 10.1007/s00726-009-0422-9
31. Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR (2004) Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 279(40):41504-41511. doi:10.1074/jbc.M407 349200 (Pubitemid 39313591)
32. Nishioka K, Melgarejo AB, Lyon RR, Mitchell MF (1995) Polyamines as biomarkers of cervical intraepithelial neoplasia. J Cell Biochem Suppl 23:87-95 (Pubitemid 26032862)
33. Palmer AJ, Wallace HM (2010) The polyamine transport system as a target for anticancer drug development. Amino Acids 38(2):415-422. doi:10.1007/s00726- 009-0400-2
34. Pegg AE (2006) Regulation of ornithine decarboxylase. J Biol Chem 281(21):14529-14532. doi:10.1074/jbc.R500031200 (Pubitemid 43855154)
35. Peralta Soler A, Gilliard G, Megosh L, George K, O'Brien TG (1998) Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res 58(8):1654-1659 (Pubitemid 28215088)
36. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
37. Schaner ME, Davidson B, Skrede M, Reich R, Florenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Trope CG, Kristensen GB, Nesland JM, Borresen-Dale AL (2005) Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer 4:26. doi: 10.1186/1476-4598-4-26 (Pubitemid 41460833)
38. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI (2003) Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14(11):4376-4386. doi:10.1091/mbc.E03-05-0279 (Pubitemid 37444641)
39. Shantz LM, Levin VA (2007) Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 33(2):213-223. doi:10.1007/s00726-007-0531-2 (Pubitemid 47222977)
40. Smith MK, Trempus CS, Gilmour SK (1998) Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Carcinogenesis 19(8):1409-1415 (Pubitemid 28409839)
41. Svensson KJ, Welch JE, Kucharzewska P, Bengtson P, Bjurberg M, Pahlman S, Ten Dam GB, Persson L, Belting M (2008) Hypoxiamediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase. Cancer Res 68(22):9291-9301. doi:10.1158/0008-5472.can-08-2340
42. Tang H, Ariki K, Ohkido M, Murakami Y, Matsufuji S, Li Z, Yamamura K (2009) Role of ornithine decarboxylase antizyme inhibitor in vivo. Genes Cells 14(1):79-87. doi:10.1111/j.1365-2443.2008.01249.x
43. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW (2010) Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 139(3):797-805, 805 e791. doi:10.1053/j.gastro.2010. 06.005
44. Tsuji T, Todd R, Meyer C, McBride J, Liao PH, Huang MF, Chou MY, DonoffRB,WongDT (1998)Reduction of ornithine decarboxylase antizyme (ODC-Az) level in the 7, 12-dimethylbenz(a)anthraceneinduced hamster buccal pouch carcinogenesis model. Oncogene 16(26):3379-3385. doi:10.1038/sj.onc.1201887 (Pubitemid 28349680)
45. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schroder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H (2005) High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosom Cancer 44(4):438-449. doi:10.1002/gcc.20259 (Pubitemid 41476795)
46. Wan T, Hu Y, Zhang W, Huang A, Yamamura K, Tang H (2010) Changes in liver gene expression of Azin1 knock-out mice. Z Naturforsch C 65(7-8):519-527
47. Zagaja GP, Shrivastav M, Fleig MJ, Marton LJ, Rinker-Schaeffer CW, Dolan ME (1998) Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol 41(6):505-512 (Pubitemid 28140716)
48. Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL (2009) Risk of cardiovascular events in a randomized placebocontrolled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res 2(3):209-212. doi:10.1158/1940-6207.capr- 08-0203